Evaluation of the Xpert® HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas. (September 2017)

• Record Type: Journal Article
• Authors: Donà, Maria Gabriella; Rollo, Francesca; Pichi, Barbara; Spriano, Giuseppe; Pellini, Raul; Covello, Renato; Pescarmona, Edoardo; Fabbri, Giulia; Scalfari, Manuela; Gheit, Tarik; Benevolo, Maria
• Is Part Of: Oral oncology. Volume 72(2017)
• Page Start: 117
• Page End: 122
• Publication Date: 2017-09
• Subjects: Orophrayngeal neoplasms -- Head and neck cancer -- Human Papillomavirus -- FFPE -- p16ink4a -- HPV DNA tests; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2017.07.016
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: The ability of the Xpert in HPV detection on FFPE orophrayngeal cancer is studied. This fast and easy assay requires no prior purification of nucleic acids. The Xpert showed a very good agreement with the INNO-LiPA and p16 findings. The Xpert represents a reliable tool for HPV testing on FFPE orophrayngeal cancer. Abstract: Objectives: The increasing incidence of HPV-related Oropharyngeal Squamous Cell Carcinoma (OPSCC) and the improved survival of HPV-positive OPSCC highlight the need for effective tools in evaluating HPV status on formalin-fixed paraffin-embedded (FFPE) cancers. To date, there is no agreement regarding the most appropriate method for HPV testing on FFPE materials. We aimed to investigate the performance of the Xpert® HPV assay (Cepheid) on crude lysates from OPSCC FFPE tissues. Materials and methods: Crude lysates were obtained by proteinase K digestion of FFPE tissues that had already been analyzed by the INNO-LiPA HPV assay and p16 ink4a immunostaining. Results: 159 FFPE OPSCCs were evaluated. All the samples provided valid results with the Xpert, whereas three samples (1.8%) were invalid using the INNO-LiPA. Among the remaining 156 cases, 65 (41.7%) were concordantly positive and 87 (55.8%) concordantly negative (raw agreement 0.97, 95% CI: 0.93–0.99; Cohen K 0.95, 95% CI: 0.90–0.99). Type-specific data for the cases that were positive by both methods were completely concordant. Three samples were HPV16-positive with Xpert but negative with INNO-LiPA, while one OPSCC tested negative with Xpert and positive with INNO-LiPA. A very good agreement was observed between the Xpert and the p16 results, which was slightly higher than that for INNO-LiPA (Cohen K 0.87 vs. 0.85). Conclusion: The Xpert HPV assay appears to be a very good method for HPV detection and genotyping on FFPE OPSCCs, and requires no prior purification of nucleic acids. This assay showed a very good agreement with INNO-LiPA and p16 findings.